Reducing severe spasticity in cerebral palsy following meningoencephalitis by botulinum toxin
AbstractA 3-year-old boy diagnosed with diplegic cerebral palsy had received Botulinum toxin injection to reduce severe spasticity. There was an improvement of muscles tone and motor function including better ability of limb flexion of the knees and hip, adduction of the hip, flexion of the toes, and plantar flexion of the foot. No side effect was observed after the procedure.
Kakooza-Mwesige A, Forssberg H, Elliasson A, Turnwine JK. Cerebral palsy in children in Kampala, Uganda: clinical subtypes, motor function and co-morbidities. BMC Res Notes. 2015;8:166. https://doi.org/10.1186/s13104-015-1125-9
Novak I, Mclntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885–910. https://doi.org/10.1111/dmcn.12246
Whelan MA, Delgado MR. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society. Neurology. 2010;75(7):669. https://doi.org/10.1212/WNL.0b013e3181ec670b
Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–43. https://doi.org/10.1212/WNL.0b013e3181cbcd2f
Pavone V, Testa G, Restivo DA, Cannavò L, Condorelli G, Portinaro NM, et al. Botulinum toxin treatment for limb spasticity in childhood cerebral palsy. Front Pharmacol. 2016;7(29):1–6. https://doi.org/10.3389/fphar.2016.00029
Bjornson K, Hays R, Graubert C, Price R, Won F, McLaughlin JF, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007;120(1):49–58. https://doi.org/10.1542/peds.2007-0016
Li SY, Qian XG, Zhao YL, Fu WJ, Tan XR, Liu ZH. Risk factors for interictal epileptiform discharges on electroencephalogram in children with spastic hemiplegic cerebral palsy. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17(12):1338–41. Chinese.
Zhu Dn, Wang MM, Wang J, Zhang W, Li HZ, Yang P, et al. Effect of botulinum toxin A injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy: a prospective study. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(12):123–9. Chinese.
Choi JY, Jung S, Rha D, Park ES. Botulinum toxin type A injection for spastic equinovarus foot in children with spastic cerebral palsy: effects on gait and foot pressure distribution. Yonsei Med J. 2016;57(2):496–504. https://doi.org/10.3349/ymj.2016.57.2.496
Cimolin V, Galli M, Crivellini M, Albertini G. Quantitative effects on proximal joints of botulinum toxin treatment for gastrocnemius spasticity: a 4-year-old case study. Case Report Med. 2009;10(985717):1–4. https://doi.org/10.1155/2009/985717
Morota N, Ihara S, Ogiwara H. Neurosurgical management of childhood spasticity: functional posterior rhizotomy and intratechal baclofen infusion therapy. Neurol Med Chir. 2015;55(8):624–39. https://doi.org/10.2176/nmc.ra.2014-0445
Molenaers G, Van Campenhout A, Fagard K, De Cat J, Desloovere K. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop. 2010;4(3):183–95. https://doi.org/10.1007/s11832-010-0246-x
Crowner BE, Torres-Russotto D, Carter AR, Racette BA. Systemic weakness after therapeutic injection of botulinum toxin A: a case series and review of the literature. Clin Neuropharmacol. 2010;33(5):243–7. https://doi.org/10.1097/WNF.0b013e3181f5329e
Copyright (c) 2017 Prastiya I. Gunawan, Darto Saharso
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.